Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31341114 | 0.78 | PDE10A (0.48) | ALDH1A1KMT2AKDM4EGAAMAPT | |
| SCHEMBL2006799 | 0.78 | CES2 (0.64) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL27517374 | 0.76 | P2RX7 (0.47) | CES2CES1KMT2AMEN1CYP1A2 | |
| SCHEMBL25338097 | 0.76 | P2RX7 (0.39) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL4703400 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL3237973 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL30976528 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL19314041 | 0.76 | CES2 (0.55) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL1279794 | 0.75 | ALDH1A1 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL10349262 | 0.75 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | claimed |
| CN-1210105-A | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | CN | claimed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | claimed |
| CN-114578043-A | ELISA kit and preparation method and detection method thereof | 伊莱瑞特(武汉)生物技术有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9708331-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| CN-1210105-A | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | CN | disclosed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| US-5837708-A | CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-17 | — | — | US | disclosed |
| CN-1170407-A | Novel sulfonamides | HOFFMANN LA ROCHE (CH) | 1998-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | CES2 765/4885CES1 960/4885L3MBTL1 3852/4885 |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | CES2 765/4885CES1 960/4885L3MBTL1 3852/4885 |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | CES2 765/4885CES1 960/4885L3MBTL1 3852/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | CES2 765/4885CES1 960/4885L3MBTL1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.